DX
Disease Management, Mechanisms, and Treatment (Poster)

Friday, May 29, 2015: 12:00 PM-2:00 PM
Griffin Hall
Disease Activity during the First Year Predicts Clinical Long-Term Outcomes in Patients with Multiple Sclerosis: Fingolimod Treatment Benefit
Pavle Repovic, MD, PhD, Swedish Medical Center; Erik Burton, MD, Novartis Pharmaceuticals Corporation; Xiangyi Meng, PhD, Novartis Pharmaceuticals Corporation; Daniela Piani Meier, MD, Novartis Pharmaceuticals Corporation; Frederik Barkhof, MD, PhD, VU University Medical Center

Lymphocyte Counts after Initiation of Dimethyl Fumerate
Yaser Almalik, MD, FRCPC, University of Calgary; Jamie Greenfield, MPH, University of Calgary; Winona Wall, BSc, University of Calgary; Luanne M Metz, MD, FRCPC, University of Calgary
PDF
Expanding Antigen-Specific T-Regulatory Type 1 CD4+ T Cells in Vivo to Treat CNS Autoimmunity
Poornima Ambalavanan, Bachelor of Technology, University of Calgary

The Safety and Efficacy of Switching from Natalizumab to Dimethyl Fumarate: Real World Experience
Faria S Amjad, MD, Medstar Georgetown University Hospital; Nasima Afsari, MBBS, Medstar Georgetown University Hospital; Carlo Tornatore, MD, Medstar Georgetown University Hospital

Assessing the Incidence of Elevation in Eosinophils with the Use of Dimethyl Fumarate in Multiple Sclerosis
Stephen Aradi, BS, USF Health Morsani College of Medicine; Robert J Soares, BS, USF Health Morsani College of Medicine; Derrick Robertson, MD, USF Health Morsani College of Medicine; Chetan Gandhy, MD, USF Health Morsani College of Medicine; Michelle Lyman, BS, USF Health Morsani College of Medicine

Lymphocyte Pharmacodynamics and Safety of Natalizumab in Patients Previously Treated with Alemtuzumab
Ann D Bass, MD, Neurology Center of San Antonio; Keith R Edwards, MD, FAAN, Multiple Sclerosis Center of Northeastern New York; Per S Sřrensen, MD, DMSc, FAAN, Danish Multiple Sclerosis Center, Rigshospitalet; Krzysztof W Selmaj, MD, PhD, Medical University of Lodz; David H Margolin, MD, PhD, Genzyme, a Sanofi company; Linda Kasten, MA, PROMETRIKA, LLC; Edward J. Fox, MD, Multiple Sclerosis Clinic of Central Texas, University of Texas Medical Branch

The Effects of Body Mass Index (BMI) on Multiple Sclerosis (MS) Progression
Aliza Ben-Zacharia, DrNP, Mount Sinai School of Medicine

Disease Activity in the First Year Predicts Clinical Outcomes in Patients with Multiple Sclerosis in the Phase 3 Freedoms and Freedoms II Studies
Aaron Boster, MD, The Ohio State University Medical Center; Kathleen Hawker, MD, Novartis Pharmaceuticals Corporation; Shannon Ritter, MD, Novartis Pharmaceuticals Corporation; Davorka Tomic, MD, Novartis Pharma AG; Till Sprenger, MD, Medical Image Analysis Center, University Hospital Basel
PDF
Clinical and MRI Benefits of IFN ß-1a 44 µg SC tiw Treatment over 1 Year in Patients with RMS: Subgroup Analyses of the PRISMS Study
Mark Cascione, MD, Tampa Neurology Associates, South Tampa Multiple Sclerosis Center; Fernando Dangond, MD, FAAN, MBA, EMD Serono, Inc.; Juanzhi Fang, BMed, MS, EMD Serono, Inc.; Aaron Miller, MD, Mount Sinai Hospital
PDF
Disease Modifying Therapy & the Decision Making Process for MS patients in NARCOMS
Stacey S Cofield, PhD, University of Alabama at Birmingham; Tuula Tyry, PhD, University of Alabama at Birmingham; Nina Thomas, MPH, Genentech, Inc; Sandre McNeal, MS, University of Alabama at Birmingham; Robert J. Fox, MD, FAAN, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic; Ruth Ann Marrie, MD, PhD, FRCPC, University of Manitoba; Gary Cutter, PhD, University of Alabama at Birmingham

Real-World Clinical Outcomes in Relapsing-Remitting Multiple Sclerosis Patients Who Switch from Natalizumab to Delayed-Release Dimethyl Fumarate
Stanley Cohan, MD, PhD, Providence Multiple Sclerosis Center; Christopher LaGanke, MD, North Central Neurology Associates; Carlo Tornatore, MD, Medstar Georgetown University Hospital; Jonathan Calkwood, MD, Schapiro Center for Multiple Sclerosis, Minneapolis Clinic of Neurology; Harold Moses, MD, Vanderbilt University Medical Center; Kyle E Smoot, MD, Providence Multiple Sclerosis Center; Monica Mann, PhD, Biogen Idec; Venkata Meka, MD, Biogen Idec; Macaulay Okwuokenye, DrPH, Biogen Idec; Christophe Hotermans, MD, PhD, Biogen Idec; Leslie Meltzer, PhD, Biogen Idec

Four-Year Expanded Disability Status Scale Outcomes in Patients Treated with Fingolimod in the Phase 3 and Extension Trial Program
Bruce A.C. Cree, MD, PhD, MCR, University of California San Francisco Medical Center; Jeffrey A Cohen, MD, Cleveland Clinic; Peter Chin, MD, Formerly Novartis Pharmaceutical Corporation; Shannon Ritter, MD, Novartis Pharmaceuticals Corporation; Daniela Piani Meier, MD, Novartis Pharma AG; Ludwig Kappos, MD, University Hospital Basel
PDF
Relapse Outcomes in Patients with Multiple Sclerosis Treated with Fingolimod: Subgroup Analyses of Three Phase 3 Fingolimod Trials
Tobias Derfuss, MD, University Hospital Basel; Daniel Ontaneda, MD, Cleveland Clinic; Jacqueline Nicholas, MD, The Ohio State University Multiple Sclerosis Center; Xiangyi Meng, PhD, Novartis Pharmaceuticals Corporation; Kathleen Hawker, MD, Novartis Pharmaceuticals Corporation
PDF
Do Oral Disease Modifying Agents (DMTs) Improve Adherence to MS Treatment? a Comparison of Oral and Injectable Drugs
Caitlin A Dionne, RN BSN MSCN, Lahey Clinic; Rik Ganguly, BS, Lahey Clinic; Ann Camac, MD, Lahey Clinic; Claudia Chaves, MD, Lahey Clinic
PDF
A Descriptive Analysis of Time to First Treatment with Disease-Modifying Drugs in Newly Diagnosed Patients with Multiple Sclerosis
Amy L Phillips, PharmD, EMD Serono, Inc.; Natalie C Edwards, MSc, Health Services Consulting Corporation; Samuel Sutherland, BA, Boston Health Economics, Inc.
PDF
Rate of Brain Volume Loss Under Long-Term Delayed-Release Dimethyl Fumarate Treatment in Relapsing-Remitting Multiple Sclerosis Patients: Results from the Endorse Study
Robert J. Fox, MD, FAAN, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic; Ludwig Kappos, MD, University Hospital Basel; Ralf Gold, MD, St. Josef Hospital, Ruhr University; Douglas L Arnold, MD, Montreal Neurological Institute, McGill University; James Potts, PhD, Biogen Idec; Annie Zhang, MD, MPH, Biogen Idec; Nuwan C Kurukulasuriya, PhD, Biogen Idec

Resource Use, Employment Status, and Escalation to Second Line Therapy in Patients from the Benefit Study 11 Years after Onset of MS Symptoms
Edward J. Fox, MD, University of Texas Medical Branch; Gilles Edan, MD, CHU-Hôpital Pontchaillou; Mark S Freedman, MD, Ottawa Hospital Research Institute; Xavier Montalbán, MD, PhD, Hospital Universitari Vall d’Hebron; Hans-Peter Hartung, MD, Heinrich-Heine University; Bernhard Hemmer, MD, PhD, Munich Cluster for Systems Neurology (SyNergy); Frederik Barkhof, MD, PhD, VU University Medical Center; Sven Schippling, MD, University Hospital Zurich; Andrea Schulze, PhD, PAREXEL International; Dirk Pleimes, MD, Myelo Therapeutics GmbH; Christoph Pohl, MD, University Hospital of Bonn; Rupert Sandbrink, MD, Heinrich-Heine University; Gustavo Suarez, MD, Bayer HealthCare Pharmaceuticals; Eva-Maria Wicklein, MD, Bayer Pharma AG; Ludwig Kappos, MD, PhD, University Hospital Basel
PDF
Consistent Efficacy of Teriflunomide in Prespecified Subgroup Analyses from a Phase 3 Trial (TOPIC) in Patients with Early Multiple Sclerosis
Edward J Fox, MD, Multiple Sclerosis Clinic of Central Texas, Central Texas Neurology Consultants; Aaron E Miller, MD, Icahn School of Medicine at Mount Sinai, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis; Philippe Truffinet, MD, Genzyme, a Sanofi company; Karthinathan Thangavelu, PhD, Genzyme, a Sanofi company; Mark S Freedman, MD, University of Ottawa and the Ottawa Hospital Research Institute
PDF
An Assessment of Factors Associated with High Costs Among Patients with Multiple Sclerosis (MS) Receiving Disease-Modifying Drug (DMD) Therapy
Molly Frean, BA, Boston Health Economics, Inc.; Julie C Locklear, PharmD, MBA, EMD Serono, Inc.; Amy L Phillips, PharmD, EMD Serono, Inc.; Joseph Menzin, PhD, Boston Health Economics, Inc.
PDF
Efficacy and Safety of Teriflunomide in Patients Switching from Other Disease-Modifying Therapies
Mark S Freedman, MD, University of Ottawa and the Ottawa Hospital Research Institute; Jerome de Seze, MD, University Hospitals of Strasbourg; Tomas P Olsson, MD, Karolinska Institute; Anna Czlonkowska, MD, Institute of Psychiatry and Neurology Warsaw; Patrick Vermersch, MD, PhD, University of Lille; Myriam Benamor, MD, Genzyme, a Sanofi company; Philippe Truffinet, MD, Genzyme, a Sanofi company; Karthinathan Thangavelu, PhD, Genzyme, a Sanofi company; Ludwig Kappos, MD, University Hospital Basel
PDF
Clinical and MRI Efficacy of IFN ß-1a SC tiw in MS Patients with More Advanced Disease (EDSS 4.0–6.0)
Mark S Freedman, MD, University of Ottawa and the Ottawa Hospital Research Institute; Brooke Hayward, SM, MBA, EMD Serono, Inc.; John Warth, PhD, EMD Serono, Inc.; Fernando Dangond, MD, FAAN, MBA, EMD Serono, Inc.
PDF
Teriflunomide Efficacy in Newly Diagnosed Patients with RMS Enrolled in the TEMSO and TOWER Studies: A Post Hoc Analysis
Jerry S Wolinsky, MD, University of Texas Health Science Center at Houston; Mark S Freedman, MD, University of Ottawa and the Ottawa Hospital Research Institute; Giancarlo Comi, MD, University Vita-Salute San Raffaele; Jean-Pierre Bouchard, MD, Laval University, Centre Hopitalier Universitaire de Québec; Ludwig Kappos, MD, University Hospital Basel; Philippe Truffinet, MD, Genzyme, a Sanofi company; Karthinathan Thangavelu, PhD, Genzyme, a Sanofi company; Steven Cavalier, MD, Genzyme, a Sanofi company; Paul O'Connor, MD, St. Michael's Hospital
PDF
1: 10 000 Is Not Zero. Lessons Learned from a Natalizumab-Related PML Case with Repeated Negative Anti-JCV Antibody Testing
Marie-Sarah Gagne Brosseau, MD, University of Washington; Gary Stobbe, MD, University of Washington; Deb Cramer, RN, University of Washington; Hillary Lipe, A.R.N.P., University of Washington; Annette Wundes, MD, University of Washington
PDF
Alemtuzumab Improves Sustained Accumulation of Disability Outcomes Using the SAD-Plus Assessment in RRMS Patients with Inadequate Efficacy Response to Prior Therapy
Gavin Giovannoni, MBBCh, PhD, Queen Mary University of London, Barts and The London School of Medicine; Jeffrey A Cohen, MD, Cleveland Clinic; Hans-Peter Hartung, MD, Heinrich-Heine University; Eva Havrdova, MD, PhD, First Faculty of Medicine, Charles University in Prague; David H Margolin, MD, PhD, Genzyme, a Sanofi company; Linda Kasten, MA, PROMETRIKA, LLC; Edward J. Fox, MD, Central Texas Neurology Consultants

Long-Term Efficacy and Safety of Daclizumab HYP in Relapsing-Remitting Multiple Sclerosis: Results from the SELECTED Extension Study
Ralf Gold, MD, St. Josef Hospital, Ruhr University; Gavin Giovannoni, MBBCh, PhD, Queen Mary University of London, Barts and The London School of Medicine; Krzysztof W Selmaj, MD, PhD, Medical University of Lodz; Eva Havrdova, MD, Charles University in Prague; Ernst-Wilhelm Radue, MD, Medical Image Analysis Center, University Hospital Basel; Till Sprenger, MD, Medical Image Analysis Center, University Hospital Basel; Dusan Stefoski, MD, Rush University Medical Center; Xavier Montalbán, MD, Hospital Universitari Vall d’Hebron; Yaoshi Wu, MS, Biogen Idec; Steven J Greenberg, MD, AbbVie Biotherapeutics Inc.; Gulden Ozen, MD, PhD, MS, Biogen Idec; Mark Beatty, MD, Biogen Idec; Jacob Elkins, MD, Biogen Idec
PDF

Baseline Demographics and Disease Characteristics from Opera Phase III Trials Evaluating Ocrelizumab in Patients with Relapsing Multiple Sclerosis
Stephen L Hauser, MD, University of California; Giancarlo Comi, MD, University Vita-Salute San Raffaele; Hans-Peter Hartung, MD, Heinrich-Heine University; Fred D. Lublin, MD, The Icahn School of Medicine at Mount Sinai; Krzysztof W Selmaj, MD, PhD, Medical University of Lodz; Anthony Traboulsee, MD, University of British Columbia; Amit Bar-Or, MD, FRCPC, Montreal Neurological Institute and Hospital, McGill University; Douglas L Arnold, MD, McGill University; Gaelle Klingelschmitt, PhD, F.Hoffmann La-Roche / Genentech; David Leppert, MD, F.Hoffmann La-Roche / Genentech; Algirdas Kakarieka, PhD, F.Hoffmann La-Roche / Genentech; Hideki Garren, MD, PhD, F.Hoffmann La-Roche / Genentech; Ludwig Kappos, MD, University Hospital Basel
PDF

Patient Experience and Tolerance of New Glatiramir Dosing
Lynda R Hillman, DNP, VA Puget Sound Healthcare; Kathy Burgess, MD, VA Puget Sound Healthcare; Wendy Miller, RN, VA Puget Sound Healthcare

Evaluation of Peginterferon Beta-1a Tolerability Profile: Gaining Consensus Using the Delphi Technique
DeRen Huang, MD, PhD, Neurology and Neuroscience Associates; Diego Centonze, MD, PhD, Policlinico Universitario Tor Vergata; June Halper, MSN, ANP, FAAN, Consortium of Multiple Sclerosis Centers; Scott D Newsome, D.O., Johns Hopkins School of Medicine; Christopher Robertson, PharmD, Biogen Idec Inc; Xiaojun You, PhD, Biogen Idec Inc; Guido Sabatella, MD, PhD, Biogen Idec Inc; Vladimir Evilevitch, MD, PhD, Biogen Idec Inc; Leslie Leahy, PhD, Biogen Idec Inc
PDF
User Trial Questionnaire and Quality of Life Responses in Patients with Multiple Sclerosis By Neurological and Cognitive Status: MOSAIC Study
Bruce L Hughes, MD, Ruan Multiple Sclerosis Center; Jonathan Calkwood, MD, Schapiro Center for Multiple Sclerosis, Minneapolis Clinic of Neurology; Brooke Hayward, SM, MBA, EMD Serono, Inc.; Fernando Dangond, MD, FAAN, MBA, EMD Serono, Inc.
PDF
Safety, Tolerability, and Pharmacokinetics of ALKS 8700, a Novel Oral Therapy for Relapsing-Remitting Multiple Sclerosis, in Healthy Subjects
Thomas L Hunt, M.D., Ph.D., PPD Development; Chandra Durairaj, Ph.D., Alkermes, Inc.; Richard Leigh-Pemberton, M.D., Alkermes, Inc.; Ying Jiang, Ph.D., Alkermes, Inc.; Joan Manthis, M.A., Alkermes, Inc.; Marjie Hard, Ph.D., Alkermes, Inc.
PDF
The Importance of Interdisciplinary Monitoring for Disease Progression in Pediatric MS
Christa Hutaff-Lee, Ph.D., Children's Hospital Colorado; Angela Canas, Ph.D., University of Colorado; Jennifer Lindwall, Ph.D., University of Colorado; Kendra Bjoraker, Ph.D., 3:1 Neuropsychology Consultants, PLLC; Teri Schreiner, M.D., University of Colorado

Infusion-Associated Reactions in Patients Receiving Alemtuzumab after Switching from Subcutaneous Interferon Beta-1a
Carolina Ionete, MD, PhD, University of Massachusetts Memorial Medical Center; Jeffrey A Cohen, MD, Cleveland Clinic; Edward J. Fox, MD, Central Texas Neurology Consultants; Hans-Peter Hartung, MD, Heinrich-Heine University; Eva Havrdova, MD, PhD, First Faculty of Medicine, Charles University in Prague; Krzysztof W Selmaj, MD, PhD, Medical University of Lodz; David H Margolin, MD, PhD, Genzyme, a Sanofi company; Linda Kasten, MA, PROMETRIKA, LLC; D Alastair S Compston, MD, University of Cambridge School of Clinical Medicine

Effects of Fingolimod on Categorical Change in T2 Lesion Volume and Clinical Outcomes in Patients with Relapsing–Remitting Multiple Sclerosis
Douglas Jeffery, MD, Cornerstone Health Care; Elisabetta Verdun, MD, Novartis Pharma AG; Daniela Piani Meier, MD, Novartis Pharma AG; Michael Meinel, MD, Formerly Novartis Pharma AG; Peter Chin, MD, Formerly Novartis Pharmaceutical Corporation; William Camu, MD, Hôpital Guide Chauliac
PDF
Brain Volume Change By Quartile and Disability Progression in Multiple Sclerosis: A 4-Year Analysis of the Phase 3 Freedoms Trial and Its Extension
Douglas Jeffery, MD, Cornerstone Health Care; Elisabetta Verdun, MD, Novartis Pharma AG; Daniela Piani Meier, MD, Novartis Pharmaceuticals Corporation; Shannon Ritter, MD, Novartis Pharmaceuticals Corporation; Ernst W Radue, MD, University Hospital Basel; William Camu, MD, Hôpital Guide Chauliac
PDF
Utilization and Switch Patterns with Dimethyl Fumarate in a Publicly-Funded Drug Plan: The First Eight Months
Charity Evans, PhD, University of Saskatchewan; Darren Nickel, PhD, University of Saskatchewan; Karlene Britton, n/a, University of Saskatchewan; Katherine Knox, MD, University of Saskatchewan
PDF
Treatment Discontinuation after Initiation of Oral Disease-Modifying Therapies in Patients with Multiple Sclerosis
John J Ko, PharmD, MS, The University of Texas at Austin; Huanxue Zhou, MS, KMK Consulting, Inc.; Tara A Nazareth, MPH, Novartis Pharmaceuticals Corporation; Vivian Herrera, DDS, MPH, Novartis Pharmaceuticals Corporation; Yunfeng Li, PhD, Novartis Pharmaceuticals Corporation; Kathleen Hawker, MD, Novartis Pharmaceuticals Corporation; Rahul Sasane, PhD, Novartis Pharmaceuticals Corporation

Medication Prescribing Patterns Associated with Multiple Sclerosis Patients Treated with Oral Disease-Modifying Therapies
John J Ko, PharmD, MS, The University of Texas at Austin; Tara A Nazareth, MPH, Novartis Pharmaceuticals Corporation; Howard Friedman, PhD, DataMed Solutions LLC.; Prakash Navaratnam, Rph, MPH, PhD, DataMed Solutions LLC.; Denise A Herriott, MPH, Indegene TTM; Rahul Sasane, PhD, Novartis Pharmaceuticals Corporation

Predictors of Adherence Using Panel Survey Data from Multiple Sclerosis Patients Currently Treated with High-Dose High-Frequency Interferons
Chris M Kozma, PhD, Independent Research Consultant; Amy L Phillips, PharmD, EMD Serono, Inc.; Julie C Locklear, PharmD, MBA, EMD Serono, Inc.
PDF
Best Practice Recommendations of Advanced Practice Clinicians for the Care of the Challenging MS Patient
John Kramer, BA, PA-C, Center for Neurological Disorders, S.C., Wheaton Franciscan Healthcare; Christina Caon, BSN, MSN, NP-C, Wayne State University School of Medicine; Gregory Bjorklund, PA-C, Sanford Health; Mary Filipi, APRN, PhD, MS Center of Nebraska; Jennifer Ravenscroft, PA-C, MSCS, Kansas City MS Center; Amy Perrin Ross, APN, MSN, CNRN, MSCN, Loyola University Medical Center; Colleen E Miller, DNS, Genzyme, a Sanofi company

The Topographical Model of Multiple Sclerosis: A New Visualization of Disease Course
Stephen Krieger, MD, Icahn School of Medicine at Mount Sinai

Predictive Value of Early MRI Measures in Patients with RRMS Receiving Interferon ß-1a SC tiw or Placebo: Post Hoc Analyses of PRISMS Data
Mark Cascione, MD, Tampa Neurology Associates, South Tampa Multiple Sclerosis Center; David Li, MD, University of British Columbia; Fernando Dangond, MD, FAAN, MBA, EMD Serono, Inc.; Juanzhi Fang, BMed, MS, EMD Serono, Inc.; Anthony Traboulsee, MD, University of British Columbia; Guojun Zhao, MD, PhD, University of British Columbia; Yan Cheng, MD, University of British Columbia; Aaron Miller, MD, Mount Sinai Hospital
PDF
Dimethyl Fumarate Effects on Lymphocyte Phenotype
Erin E Longbrake, MD, PhD, Washington University; Michael J Ramsbottom, BS, Washington University; Laura Piccio, MD/PhD, Washington University; Anne H Cross, MD, Washington University

Investigation of the Effectiveness and Tolerability of Colesevelam HCl for Accelerated Elimination of Teriflunomide in Healthy Subjects
Catherine Lunven, PhD, Sanofi R&D; Zuyu Guo, PhD, Sanofi US; Sandrine Turpault, PharmD, Sanofi US; Astrid Delfolie, MSc, Sanofi R&D; Nicolas Fauchoux, MD, Biotrial; Timothy Turner, PhD, Genzyme, a Sanofi company; Francesca Baldinetti, MD, Genzyme, a Sanofi company
PDF
Transverse Myelitis Presenting in a Patient with Hughes-Stovin Syndrome
Jason H Margolesky, MD, University of Miami; Leticia Tornes, MD, University of Miami

Effect of Oral Fingolimod Treatment on Annualized Relapse Rates in Patients with Relapsing–Remitting Multiple Sclerosis Using Bayesian Methodology
Guosheng Yin, MD, The University of Hong Kong; Xiangyi Meng, PhD, Novartis Pharmaceuticals Corporation; Zahur Islam, PhD, Novartis Pharmaceuticals Corporation; Ralph Kern, MD, Novartis Pharmaceuticals Corporation
PDF

An Assessment of Adherence Among Multiple Sclerosis Patients Newly Initiating Treatment with a Self-Injectable Versus Oral Disease-Modifying Drug
Michael Munsell, BA, Boston Health Economics, Inc.; Julie C Locklear, PharmD, MBA, EMD Serono, Inc.; Amy L Phillips, PharmD, EMD Serono, Inc.; Molly Frean, BA, Boston Health Economics, Inc.; Joseph Menzin, PhD, Boston Health Economics, Inc.
PDF
Oligoclonal Banding Patterns in Patients with Multiple Sclerosis
Kayleigh Da, B.Sc., Fraser Health Multiple Sclerosis Clinic; Jill R Nelson, RN BScN MSCN, Fraser Health Multiple Sclerosis Clinic; George Medvedev, MD, FRCPC, Fraser Health Multiple Sclerosis Clinic; Galina Vorobeychik, MD, FRCPS(C), CMSC, Fraser Health Multiple Sclerosis Clinic
PDF
Shared Decision Making in Multiple Sclerosis: Lessons Learned from Creating New Dmt Option Grid Decision Support Tools
Karen Winn, NP, MSN, DNP, MGH Institute of Health Professions, Boston, MA; Brant J. Oliver, PhD, NP, MSN, MPH, MSCN, MGH Institute of Health Professions, Boston, MA; Pamela Newland, PhD, RN, Goldfarb School of Nursing

Peginterferon Beta-1a and Management Strategies for Flu-like Symptoms and Injection Site Reactions: Obtaining Recommendations Using the Delphi Technique
Scott D Newsome, D.O., Johns Hopkins School of Medicine; Diego Centonze, MD, PhD, Policlinico Universitario Tor Vergata; DeRen Huang, MD, PhD, Neurology and Neuroscience Associates; June Halper, MSN, ANP, FAAN, Consortium of Multiple Sclerosis Centers; Christopher Robertson, PharmD, Biogen Idec Inc; Xiaojun You, PhD, Biogen Idec Inc; Guido Sabatella, MD, PhD, Biogen Idec Inc; Vladimir Evilevitch, MD, PhD, Biogen Idec Inc; Leslie Leahy, PhD, Biogen Idec Inc
PDF
Peginterferon Beta-1a Advance Study: Subgroup Analysis over 2 Years
Scott D Newsome, D.O., Johns Hopkins School of Medicine; Bernd C Kieseier, MD, Heinrich-Heine University; Douglas L Arnold, MD, Montreal Neurological Institute, McGill University; Shulian Shang, PhD, Biogen Idec Inc.; Serena Hung, MD, Biogen Idec Inc.; Bjorn Sperling, MD, Biogen Idec Inc.

Effects of Peginterferon Beta-1a on Visual Dysfunction in Multiple Sclerosis
Scott D Newsome, D.O., Johns Hopkins University; Laura J Balcer, MD, New York University; Shulian Shang, PhD, Biogen Idec Inc.; Shifang Liu, PhD, Biogen Idec Inc.; Serena Hung, MD, Biogen Idec Inc.; Bjorn Sperling, MD, Biogen Idec Inc.

: Relapse Outcomes in Patients with Multiple Sclerosis Treated with Fingolimod after Previous Treatment with Injectable Disease-Modifying Therapies
Jacqueline Nicholas, MD, The Ohio State University Multiple Sclerosis Center; Tobias Derfuss, MD, University Hospital Basel; Daniel Ontaneda, MD, Cleveland Clinic; Xiangyi Meng, PhD, Novartis Pharmaceuticals Corporation; Kathleen Hawker, MD, Novartis Pharmaceuticals Corporation
PDF
CPT1 inhibitor significantly induce remyelination and neuroprotection in Multiple Sclerosis by a dual mode of action
John D Nieland, PhD. Assoc. Prof., Aalborg University; Jette GK Nieland, Msc, Meta-IQ ApS; Soeren Nielsen, MD. Prof., Aalborg University

Relapse Outcomes in Patients Treated with Fingolimod According to Disease Duration
Daniel Ontaneda, MD, Cleveland Clinic; Tobias Derfuss, MD, University Hospital Basel; Jacqueline Nicholas, MD, The Ohio State University Multiple Sclerosis Center; Xiangyi Meng, PhD, Novartis Pharmaceuticals Corporation; Kathleen Hawker, MD, Novartis Pharmaceuticals Corporation
PDF
Effects of Monthly Pulse Methylprednisolone Therapy on Sustained Disease Progression in Secondary Progressive Multiple Sclerosis
Serkan Ozakbas, Professor Of Neurology, Dokuz Eylul University; Bilge Piri Cinar, MD, Giresun State Hospital; Gorkem Kosehasanogullari, MD, Usak State Hospital; Turhan Kahraman, MSc, PT, Dokuz Eylul University

Tolerability Results from Year 1 of the PRISMS-2 Two-Year Randomized Controlled Trial of IFN ß-1a SC tiw Compared with Placebo
Amy Perrin Ross, APN, MSN, CNRN, MSCN, Loyola University Medical Center; Juanzhi Fang, BMed, MS, EMD Serono, Inc.; Fernando Dangond, MD, FAAN, MBA, EMD Serono, Inc.
PDF
Patient Satisfaction with the Betaconnect^TM Autoinjector for Interferon Beta-1b
Tjalf Ziemssen, MD, PhD, University Hospital Carl Gustav Carus at the Technical University of Dresden; Lauren Sylvester, BS, Bayer HealthCare Pharmaceuticals; Mark Rametta, DO, Bayer HealthCare Pharmaceuticals; Ivonne Weller, Patient Communication Executive, Bayer Vital GmbH; Julika Vogelreuter, Apothekerin, Dr. rer. medic, Bayer Vital GmbH; Anna Saake, Student Apprentice, Bayer Vital GmbH; Thomas Schreiner, Diplom-Chemiker, Dr. rer. nat, Bayer Vital GmbH; Nicolas Petroff, MA, Vitartis Medizin-Service GmbH; Amy Perrin Ross, APN, MSN, CNRN, MSCN, Loyola University Medical Center
PDF
Long-Term Follow-up of the Safety of Delayed-Release Dimethyl Fumarate in Relapsing-Remitting Multiple Sclerosis: Interim Results from the ENDORSE Extension Study
J. Theodore Phillips, MD, PhD, FAAN, Baylor Institute for Immunology Research; Robert J. Fox, MD, FAAN, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic; Krzysztof W Selmaj, MD, PhD, Medical University of Lodz; Carlo Pozzilli, MD, Faculty of Medicine, Sapienza University of Rome; Ray Zhang, PhD, Biogen Idec, Inc.; Mark Novas, MD, Biogen Idec, Inc.; Marianne T. Sweetser, MD, PhD, Biogen Idec, Inc.; Ralf Gold, MD, St. Josef Hospital, Ruhr University

Use of a Delphi Process to Gain Consensus on Effective Management of Gastrointestinal Side Effects Associated with Delayed-Release Dimethyl Fumarate
J. Theodore Phillips, MD, PhD, FAAN, Baylor Institute for Immunology Research; April Erwin, MD, The NeuroMedical Center Clinic; Stephanie Agrella, RN, MSN, APRN, ANP-BC, MSCN, Multiple Sclerosis Clinic of Central Texas; Marcelo Kremenchutzky, MD, Western University and London Health Sciences Centre; John Kramer, BA, PA-C, Center For Neurological Disorders; Jonathan Kendter, PharmD, Biogen Idec; Heather Abourjaily, PharmD, Biogen Idec; Jitesh Rana, MD, Biogen Idec; Robert J. Fox, MD, FAAN, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic
PDF
Predictive Value of MRI Measures in Patients with Relapsing Multiple Sclerosis Receiving IFN ß-1a SC tiw or IFN ß-1a IM qw: Post Hoc Analyses of EVIDENCE Data
Anthony T Reder, MD, University of Chicago; Mark S Freedman, MD, University of Ottawa and the Ottawa Hospital Research Institute; Fernando Dangond, MD, FAAN, MBA, EMD Serono, Inc.; Juanzhi Fang, BMed, MS, EMD Serono, Inc.; Patricia K Coyle, MD, Stony Brook University Medical Center
PDF
MS Medication Utilization in Texas Medicaid
Kristin M Richards, PhD, The University of Texas at Austin; Kenneth A Lawson, PhD, The University of Texas at Austin; Tara A Nazareth, MPH, Novartis Pharmaceuticals Corporation; Huanxue Zhou, MS, KMK Consulting, Inc.; Erik Burton, MD, Novartis Pharmaceuticals Corporation; Tzy-Chyi Yu, MHA, PhD, Novartis Pharmaceuticals Corporation; Rahul Sasane, PhD, Novartis Pharmaceuticals Corporation

A Comprehensive Analysis of Relapse in Multiple Sclerosis
Emily S Riser, MD, Tanner Center for MS; Jian Han, MD PhD, HudsonAlpha Institute for Biotechnology; Thomas Denney, PhD, Auburn University; Miranda B Steele, PhD, HudsonAlpha Institute for Biotechnology
PDF

Potential Association of Aspartame with MS Relapse
Lindsay A Ross, B.S., B.A., MD Candidate (Class of 2016), University of Toledo College of Medicine; Boyd M Koffman, M.D., Ph.D, University of Toledo Health Sciences Campus

Improvements in Quality of Life Are Maintained in Alemtuzumab-Treated RRMS Patients Who Develop Autoimmune Adverse Events: Care-MS II
Barry Singer, MD, The MS Center for Innovations in Care, Missouri Baptist Medical Center; Gavin Giovannoni, MBBCh, PhD, Queen Mary University of London, Barts and The London School of Medicine; Hans-Peter Hartung, MD, Heinrich-Heine University; David H Margolin, MD, PhD, Genzyme, a Sanofi company; Linda Kasten, MA, PROMETRIKA, LLC; Jeffrey A Cohen, MD, Cleveland Clinic

Fingolimod First-Dose Effects in the PREFERMS Real-World Study of Patients with Relapsing–Remitting Multiple Sclerosis
Nadia Tenenbaum, MD, Novartis Pharmaceuticals Corporation; Xiangyi Meng, PhD, Novartis Pharmaceuticals Corporation; Lesley Schofield, PhD, Novartis Pharmaceuticals Corporation; Kathleen Hawker, MD, Novartis Pharmaceuticals Corporation
PDF
Development of Chronic Black Holes (CBH) Predicts Long Term Disability: Post-Hoc Analysis of Magnetic Resonance Imaging Data (MRI) in the Prisms Study
Anthony Traboulsee, MD, University of British Columbia; David K Li, MD, FRCPC, University of British Columbia; Juanzhi Fang, BMed, MS, EMD Serono, Inc.; Fernando Dangond, MD, FAAN, MBA, EMD Serono, Inc.

Patient Perspectives on Insurance Changes and Therapy Decisions in Narcoms
Stacey S Cofield, PhD, University of Alabama at Birmingham; Tuula Tyry, PhD, St. Joseph's Hospital and Medical Center; Amber R Salter, MPH, University of Alabama at Birmingham; Sandre McNeal, MS, University of Alabama at Birmingham; Robert J. Fox, MD, FAAN, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic; Ruth Ann Marrie, MD, PhD, FRCPC, University of Manitoba; Gary Cutter, PhD, University of Alabama at Birmingham; Guoqiao Wang, PhD, University of Alabama at Birmingham

See more of: Poster